Spinal Fusion Pipeline Analysis Report 2025
Description
Around 20% of the United States population is expected to be over 65 by 2030. With the rising aging population, the incidence of spinal fusion procedures is expected to increase in the coming years. Moreover, spinal injuries are a leading cause of spinal fusion procedures. The World Health Organisation reveals that over 15 million worldwide are living with spinal cord injury (SCI). Hence, researchers are focusing on building a robust portfolio that can be put to use to manage the condition effectively.
Report Coverage
The Spinal Fusion Pipeline Report by Expert Market Research gives comprehensive insights into ongoing spinal fusion clinical trials. It covers various aspects related to the details of spinal fusion drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The spinal fusion pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from spinal fusion.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing spinal fusion pipeline development activities are covered. Moreover, spinal fusion collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Spinal Fusion Drug Pipeline Outlook
Spinal fusion involves the process of joining two or more spinal bones. The connection prevents movement and inhibits pain. During a spinal infusion surgery, a healthcare provider may use bonelike material, metal plates, screws or rods to hold bones together. This allows the bone to fuse and recover. Spinal fusion can help with the symptoms of degenerative disk disease, spinal stenosis, scoliosis, spondylolisthesis and tumor among others.
The spinal fusion treatment landscape involves the use of drugs and medications, that are often used to manage pain, and inflammation associated with the condition. In addition, bone growth stimulators and vitamin D supplements are also used to support bone health and expedite healing. Healthcare providers follow a multidisciplinary approach to optimize patient recovery and ensure procedure success. Currently, oxycodone and methocarbamol are commonly used in spinal fusion procedures. While oxycodone is an analgesic, methocarbamol is a skeletal muscle relaxant often prescribed post-operatively. Researchers are working on developing various drugs that help in manage the condition with higher efficacy.
Spinal Fusion – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of spinal fusion drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
EMR’s spinal fusion therapeutic assessment report covers 50+ drug analyses based on drug classes:
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration:
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase IV covers a major share of the total spinal fusion clinical trials. There are around 65 drugs in phase IV of spinal fusion drugs.
Spinal Fusion – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under spinal fusion pipeline analysis include analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, neuropathic pain medications, bone growth stimulating agents, corticosteroids, and antibiotics. Each drug class has a specific function and is administered based on patient specifications.
Spinal Fusion Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR spinal fusion drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in spinal fusion clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for spinal fusion. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of spinal fusion drug candidates.
Pregabalin
This is a neuropathic pain drug that is being tested to treat multi-modal pain regimen post-spinal surgery. Sponsored by the Hospital for Special Surgery, New York, the drug is currently in phase IV clinical trials.
Ketorolac
Sponsored by the Ascension South East Michigan, this spinal fusion drug candidate is a low-dose ketorolac under investigation as an analgesic during the early post-operative period (within 48 hours) of spinal fusion.
Tranexamic Acid
Tranexamic acid is being evaluated as an alternative to reduce bleeding in individuals undergoing spinal fusion surgery. Sponsored by Exela Pharma Sciences, LLC, it is in Phase 3 of a multicenter, randomized, double-blind, parallel-group study.
Reasons To Buy This Report
The Spinal Fusion Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for spinal fusion. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into spinal fusion collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Key Questions Answered in the Spinal Fusion – Pipeline Insight Report
Spinal Fusion Devices Market
Spinal Cord Injury Market
Spinal Implants and Surgery Devices
Report Coverage
The Spinal Fusion Pipeline Report by Expert Market Research gives comprehensive insights into ongoing spinal fusion clinical trials. It covers various aspects related to the details of spinal fusion drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The spinal fusion pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from spinal fusion.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing spinal fusion pipeline development activities are covered. Moreover, spinal fusion collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Spinal Fusion Drug Pipeline Outlook
Spinal fusion involves the process of joining two or more spinal bones. The connection prevents movement and inhibits pain. During a spinal infusion surgery, a healthcare provider may use bonelike material, metal plates, screws or rods to hold bones together. This allows the bone to fuse and recover. Spinal fusion can help with the symptoms of degenerative disk disease, spinal stenosis, scoliosis, spondylolisthesis and tumor among others.
The spinal fusion treatment landscape involves the use of drugs and medications, that are often used to manage pain, and inflammation associated with the condition. In addition, bone growth stimulators and vitamin D supplements are also used to support bone health and expedite healing. Healthcare providers follow a multidisciplinary approach to optimize patient recovery and ensure procedure success. Currently, oxycodone and methocarbamol are commonly used in spinal fusion procedures. While oxycodone is an analgesic, methocarbamol is a skeletal muscle relaxant often prescribed post-operatively. Researchers are working on developing various drugs that help in manage the condition with higher efficacy.
Spinal Fusion – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of spinal fusion drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s spinal fusion therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Analgesics
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Muscle Relaxants
- Neuropathic Pain Medications
- Bone Growth Stimulating Agents
- Corticosteroids
- Antibiotics
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase IV covers a major share of the total spinal fusion clinical trials. There are around 65 drugs in phase IV of spinal fusion drugs.
Spinal Fusion – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under spinal fusion pipeline analysis include analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, neuropathic pain medications, bone growth stimulating agents, corticosteroids, and antibiotics. Each drug class has a specific function and is administered based on patient specifications.
Spinal Fusion Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR spinal fusion drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in spinal fusion clinical trials:
- Kuros BioSciences B.V.
- Zimmer Biomet
- Novo Nordisk A/S
- Pacira Pharmaceuticals, Inc.
- Exela Pharma Sciences, LLC.
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for spinal fusion. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of spinal fusion drug candidates.
Pregabalin
This is a neuropathic pain drug that is being tested to treat multi-modal pain regimen post-spinal surgery. Sponsored by the Hospital for Special Surgery, New York, the drug is currently in phase IV clinical trials.
Ketorolac
Sponsored by the Ascension South East Michigan, this spinal fusion drug candidate is a low-dose ketorolac under investigation as an analgesic during the early post-operative period (within 48 hours) of spinal fusion.
Tranexamic Acid
Tranexamic acid is being evaluated as an alternative to reduce bleeding in individuals undergoing spinal fusion surgery. Sponsored by Exela Pharma Sciences, LLC, it is in Phase 3 of a multicenter, randomized, double-blind, parallel-group study.
Reasons To Buy This Report
The Spinal Fusion Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for spinal fusion. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into spinal fusion collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Key Questions Answered in the Spinal Fusion – Pipeline Insight Report
- Which companies/institutions are leading the spinal fusion drug development?
- What is the efficacy and safety profile of spinal fusion pipeline drugs?
- Which company is leading the spinal fusion pipeline development activities?
- What is the current spinal fusion commercial assessment?
- What are the opportunities and challenges present in the spinal fusion drug pipeline landscape?
- What is the efficacy and safety profile of spinal fusion pipeline drugs?
- Which company is conducting major trials for spinal fusion drugs?
- Which companies/institutions are involved in spinal fusion collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in spinal fusion?
Spinal Fusion Devices Market
Spinal Cord Injury Market
Spinal Implants and Surgery Devices
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Spinal Fusion
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Spinal Fusion: Epidemiology Snapshot
- 5.1 Spinal Fusion Incidence by Key Markets
- 5.2 Spinal Fusion– Patients Seeking Treatment in Key Markets
- 6 Spinal Fusion: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Spinal Fusion: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Spinal Fusion, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Spinal Fusion Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Spinal Fusion Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Ketorolac
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Pregabalin
- 10.2.3 Dexmedetomidine
- 10.2.4 Vancomycin
- 10.2.5 Other Drug
- 11 Spinal Fusion Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Abaloparatide
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Other Drugs
- 12 Spinal Fusion Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Dexamethasone Injection
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 EXPAREL
- 12.2.3 Other Drugs
- 13 Spinal Fusion Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Drug 2
- 13.2.3 Other Drugs
- 14 Spinal Fusion, Key Drug Pipeline Companies
- 14.1 Kuros BioSciences B.V.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Zimmer Biomet
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Novo Nordisk A/S
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Exela Pharma Sciences, LLC.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Pacira Pharmaceuticals, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
